RT Journal Article
SR Electronic
T1 Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1349
OP 1351
VO 31
IS 7
A1 Takehiko Mori
A1 Hideto Kameda
A1 Hiroe Ogawa
A1 Atsushi Iizuka
A1 Naoya Sekiguchi
A1 Hirofumi Takei
A1 Hayato Nagasawa
A1 Michihide Tokuhira
A1 Toshio Tanaka
A1 Yumiko Saito
A1 Koichi Amano
A1 Toru Abe
A1 Tsutomu Takeuchi
YR 2004
UL http://www.jrheum.org/content/31/7/1349.abstract
AB OBJECTIVE: To evaluate the incidence and effect of cytomegalovirus (CMV) reactivation in patients with inflammatory connective tissue diseases (CTD) undergoing immunosuppressive therapy. METHODS: A total of 18 consecutive CMV seropositive patients undergoing immunosuppressive therapy for inflammatory CTD were enrolled. CMV reactivation was determined by detection of CMV-DNA in peripheral blood leukocytes (PBL) or plasma using quantitative real-time polymerase chain reaction. RESULTS: CMV reactivation was detected in PBL in 7 of 17 evaluable patients (41%), and in plasma in 5 of 17 patients (29%). Patients with detectable CMV-DNA in plasma were exclusively positive for CMV-DNA in PBL. Conclusion. Patients with inflammatory CTD under immunosuppressive therapy are at high risk for CMV reactivation. The clinical significance of such an event and indications for antiviral therapy should be examined further.